Scispot, the creator of the best tech stack for modern biotech, announces that Persist AI, an AI-driven biotech company specializing in the creation of long-acting microsphere formulations, has selected them to provide a robust data infrastructure. This partnership aims to automate Persist AI’s research workflows and scale its AI capabilities. Persist AI is currently utilizing Scispot as its primary data and workflow management platform, effectively gathering and integrating data from diverse sources, thereby optimizing its use in machine learning and artificial intelligence processes.
Latest Insights: How to Get Started with Prompt Engineering in Generative AI Projects
Persist AI is committed to slashing drug formulation development time by 50% to just 2 years through the power of AI-driven automation. Traditional methods would typically see pharmaceutical companies investing approximately five years to develop long-lasting drug formulations. However, with Persist AI’s integration of advanced AI automation, the process is accelerated, targeting a 50% reduction in overall development time. Using Scispot’s flexible platform, Persist AI is geared towards designing long-lasting injections that allow for slow drug release over prolonged periods. The AI models, trained using patterns extrapolated from a range of experiments, predict drug release rates and enhance formulation efficiency. This game-changing approach is set to revolutionize patient experience and adherence to treatments.
Recommended: AiThority Interview with Brigette McInnis-Day, Chief People Officer at UiPath
“As an AI-focused biotech company, digitizing and automating our processes from the get-go has been imperative. Scispot has been instrumental in establishing the right digital foundation to achieve this objective,” stated Karthik Raman, Founder & CEO of Persist AI. “Scispot organizes not just experimental, but also organizational data, optimizing resource utilization. With the aid of Scispot’s robust data management system, we have been able to connect our in silico data with the automated experiments we perform in the real world and to track resources like lab materials which are utilized in each batch.”
“We at Scispot feel a deep synergy with Persist AI’s objective, which resonates with our mission of reducing the time it takes to bring new drugs to market,” stated Guru Singh, Founder & CEO of Scispot. “We strive to empower modern biotech companies with our advanced data infrastructure, supporting their transformation into full-fledged Digital Biotech entities. Persist AI epitomizes this transformation, and we are thrilled to support their commitment to delivering life-saving solutions more rapidly to the marketplace.”
Persist AI’s digital transformation journey with Scispot has yielded substantial enhancements in their research and development processes. Formerly dependent on Excel and Google Sheets, Persist AI required a solution capable of efficiently accommodating their growing demands, all while preserving comprehensive versioning and data integrity. Scispot’s extensive capabilities have established a centralized hub, negating the necessity to manage numerous Excel sheets and facilitating smooth permissions for team members. The implementation of Scispot has led to improved organization, streamlined procedures, and automated data management.
As the digital era evolves, Scispot has secured its position as the tech stack of choice for modern biotech companies, particularly those focusing on machine learning and artificial intelligence. With its API-friendly electronic lab notebook (ELN) and lab information management system (LIMS), Scispot expertly marshals all R&D data. This strategic approach paves the way for smooth integration with advanced machine learning and AI, enabling companies to expedite their path to groundbreaking innovations.
Latest Interview Insights : AiThority Interview with Abhay Parasnis, Founder and CEO at Typeface
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.